secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K/A
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001723128-24-000044
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal Q3 net revenue up 13% to $702M; adjusted EBITDA $158M, guidance affirmed
-------------------------------------------------------------------------------

- Net revenue $702M (+13% YoY); GAAP net loss ~$0.2M vs prior year net income of $10M.
- Adjusted EBITDA $158M (+2% YoY); adjusted diluted EPS $0.16 vs $0.19 prior year.
- Generics +9%, Specialty +19% driven by CREXONT/ONGENTYS launches; AvKARE +21%.
- Affirms full-year 2024 guidance; launched CREXONT, collaboration with Metsera, in-licensed biosimilar.
- Higher interest expense drove GAAP net loss and lower adjusted EPS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000172312824000044/0001723128-24-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000172312824000044/amrx-20241108.htm
  HTML page:      https://secwatch.observer/filing/0001723128-24-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer